Abstract
The importance of Chlamydia trachomatis as an etiologic agent in the development of pelvic inflammatory disease (PID) is well documented. Although there are numerous antimicrobial agents that are effective against C. trachomatis, one of the most frequent combinations that is used to treat PID is clindamycin and gentamicin. The efficacy of clindamycin as the sole treatment for chlamydial infections has been questioned. In fact, the Centers for Disease Control (Atlanta, Ga.) has recommended the use of doxycycline following clindamycin and gentamicin treatment of PID confirmed or suspected to be caused by C. trachomatis. This study was designed to determine whether there is any synergistic in vitro activity between clindamycin and gentamicin or tobramycin on inhibition of C. trachomatis replication. In this experiment, the MIC of clindamycin decreased two- to threefold when an aminoglycoside was added. This occurred even though aminoglycosides by themselves had essentially no effect against C. trachomatis. The mechanism of this interaction is uncertain.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Berenbaum M. C. A method for testing for synergy with any number of agents. J Infect Dis. 1978 Feb;137(2):122–130. doi: 10.1093/infdis/137.2.122. [DOI] [PubMed] [Google Scholar]
- Bowie W. R., Yu J. S., Jones H. D. Partial efficacy of clindamycin against Chlamydia trachomatis in men with nongonococcal urethritis. Sex Transm Dis. 1986 Apr-Jun;13(2):76–80. doi: 10.1097/00007435-198604000-00005. [DOI] [PubMed] [Google Scholar]
- Christensen J. J., Holten-Andersen W., Nielsen P. B. Chlamydia trachomatis: in vitro susceptibility to antibiotics singly and in combination. Acta Pathol Microbiol Immunol Scand B. 1986 Oct;94(5):329–332. doi: 10.1111/j.1699-0463.1986.tb03061.x. [DOI] [PubMed] [Google Scholar]
- Gjønnaess H., Dalaker K., Anestad G., Mårdh P. A., Kvile G., Bergan T. Pelvic inflammatory disease: etiologic studies with emphasis on chlamydial infection. Obstet Gynecol. 1982 May;59(5):550–555. [PubMed] [Google Scholar]
- Harrison H. R., Riggin R. M., Alexander E. R., Weinstein L. In vitro activity of clindamycin against strains of Chlamydia trachomatis, Mycoplasma hominis, and Ureaplasma urealyticum isolated from pregnant women. Am J Obstet Gynecol. 1984 Jul 1;149(5):477–480. doi: 10.1016/0002-9378(84)90019-x. [DOI] [PubMed] [Google Scholar]
- Hemsell D. L., Hemsell P. G., Heard M. C., Nobles B. J. Piperacillin and a combination of clindamycin and gentamicin for the treatment of hospital and community acquired acute pelvic infections including pelvic abscess. Surg Gynecol Obstet. 1987 Sep;165(3):223–229. [PubMed] [Google Scholar]
- How S. J., Hobson D., Hart C. A., Webster R. E. An in-vitro investigation of synergy and antagonism between antimicrobials against Chlamydia trachomatis. J Antimicrob Chemother. 1985 May;15(5):533–538. doi: 10.1093/jac/15.5.533. [DOI] [PubMed] [Google Scholar]
- Norden C. W., Wentzel H., Keleti E. Comparison of techniques for measurement of in vitro antibiotic synergism. J Infect Dis. 1979 Oct;140(4):629–633. doi: 10.1093/infdis/140.4.629. [DOI] [PubMed] [Google Scholar]
- Thompson S. E., Washington A. E. Epidemiology of sexually transmitted Chlamydia trachomatis infections. Epidemiol Rev. 1983;5:96–123. doi: 10.1093/oxfordjournals.epirev.a036266. [DOI] [PubMed] [Google Scholar]
- Washington A. E., Cates W., Jr, Zaidi A. A. Hospitalizations for pelvic inflammatory disease. Epidemiology and trends in the United States, 1975 to 1981. JAMA. 1984 May 18;251(19):2529–2533. doi: 10.1001/jama.251.19.2529. [DOI] [PubMed] [Google Scholar]
- Wasserheit J. N., Bell T. A., Kiviat N. B., Wølner-Hanssen P., Zabriskie V., Kirby B. D., Prince E. C., Holmes K. K., Stamm W. E., Eschenbach D. A. Microbial causes of proven pelvic inflammatory disease and efficacy of clindamycin and tobramycin. Ann Intern Med. 1986 Feb;104(2):187–193. doi: 10.7326/0003-4819-104-2-187. [DOI] [PubMed] [Google Scholar]